BUZZ-H.C. Wainwright upgrades Rapt Therapeutics to 'buy' after allergy drug license deal

Reuters

Dec 26, 2024

BUZZ-H<a href="https://laohu8.com/S/02403">.C</a>. Wainwright upgrades Rapt <a href="https://laohu8.com/S/LENZ">Therapeutics</a> to 'buy' after allergy drug license deal

** Brokerage H.C. Wainwright upgrades drug developer Rapt Therapeutics RAPT.O to 'buy' from 'neutral'

** Co entered into a license agreement with China-based Shanghai Jemincare Pharmaceutical Co for an experimental allergy treatment called RPT904

** RAPT plans to develop RPT904 initially for food allergy

** Brokerage says "investors should note that the food allergy market represents a large and lucrative niche," estimates that about 33 mln people suffer from at least one food allergy in the US

** Brokerage projects peak annual sales of $5.4 bln by 2037 for RPT904, assuming U.S. launch in 2031

** Says RPT904 could achieve peak sales approaching $500M for chronic spontaneous urticaria (CSU) — a skin condition

** Brokerage estimates a 40% probability of approval of RPT904 for food allergy and a 30% probability of approval for CSU

** Up to last close, stock down 93% YTD

(Reporting by Sneha S K)

((Sneha.SK@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2494854380"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2494854380\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2494854380?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-26 20:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2494854380","market":"us","top_or_hot":-1,"title":"BUZZ-H.C. Wainwright upgrades Rapt Therapeutics to 'buy' after allergy drug license deal","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-H<a href=\"https://laohu8.com/S/02403\">.C</a>. Wainwright upgrades Rapt <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> to 'buy' after allergy drug license deal</title></head><body><p>** Brokerage H.C. Wainwright upgrades drug developer Rapt Therapeutics <span>RAPT.O</span> to 'buy' from 'neutral'</p><p>** Co <span>entered</span> into a license agreement with China-based Shanghai Jemincare Pharmaceutical Co for an experimental allergy treatment called RPT904</p><p>** RAPT plans to develop RPT904 initially for food allergy</p><p>** Brokerage says \"investors should note that the food allergy market represents a large and lucrative niche,\" estimates that about 33 mln people suffer from at least one food allergy in the US </p><p>** Brokerage projects peak annual sales of $5.4 bln by 2037 for RPT904, assuming U.S. launch in 2031</p><p>** Says RPT904 could achieve peak sales approaching $500M for chronic spontaneous urticaria (CSU) — a skin condition</p><p>** Brokerage estimates a 40% probability of approval of RPT904 for food allergy and a 30% probability of approval for CSU</p><p>** Up to last close, stock down 93% YTD </p><p> (Reporting by Sneha S K)</p><p> ((Sneha.SK@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-H.C. Wainwright upgrades Rapt Therapeutics to 'buy' after allergy drug license deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-H.C. Wainwright upgrades Rapt Therapeutics to 'buy' after allergy drug license deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2024-12-26 20:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-H<a href=\"https://laohu8.com/S/02403\">.C</a>. Wainwright upgrades Rapt <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> to 'buy' after allergy drug license deal</title></head><body><p>** Brokerage H.C. Wainwright upgrades drug developer Rapt Therapeutics <span>RAPT.O</span> to 'buy' from 'neutral'</p><p>** Co <span>entered</span> into a license agreement with China-based Shanghai Jemincare Pharmaceutical Co for an experimental allergy treatment called RPT904</p><p>** RAPT plans to develop RPT904 initially for food allergy</p><p>** Brokerage says \"investors should note that the food allergy market represents a large and lucrative niche,\" estimates that about 33 mln people suffer from at least one food allergy in the US </p><p>** Brokerage projects peak annual sales of $5.4 bln by 2037 for RPT904, assuming U.S. launch in 2031</p><p>** Says RPT904 could achieve peak sales approaching $500M for chronic spontaneous urticaria (CSU) — a skin condition</p><p>** Brokerage estimates a 40% probability of approval of RPT904 for food allergy and a 30% probability of approval for CSU</p><p>** Up to last close, stock down 93% YTD </p><p> (Reporting by Sneha S K)</p><p> ((Sneha.SK@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RAPT","symbol_name":"RAPT Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241226:nL4N3NR0GT:1","article_id":"2494854380","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2494854380","pubTimestamp":1735214761,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-H.C. Wainwright upgrades Rapt Therapeutics to 'buy' after allergy drug license deal** Brokerage H.C. Wainwright upgrades drug developer Rapt Therapeutics RAPT.O to 'buy' from 'neutral'** Co entered into a license agreement with China-based Shanghai Jemincare Pharmaceutical Co for an experimental allergy treatment called RPT904** RAPT plans to develop RPT904 initially for food allergy** Brokerage says \"investors should note that the food allergy market represents a large and lucrative niche,\" estimates that about 33 mln people suffer from at least one food allergy in the US ** Brokerage projects peak annual sales of $5.4 bln by 2037 for RPT904, assuming U.S. launch in 2031** Says RPT904 could achieve peak sales approaching $500M for chronic spontaneous urticaria  — a skin condition** Brokerage estimates a 40% probability of approval of RPT904 for food allergy and a 30% probability of approval for CSU** Up to last close, stock down 93% YTD   ","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"RAPT":"RAPT Therapeutics, Inc."},"translate_title":"巴斯-H.C。Wainwright在过敏药物许可协议后将Rapt Therapeutics升级为“买入”","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RAPT":0.9},"content_text":"BUZZ-H.C. Wainwright upgrades Rapt Therapeutics to 'buy' after allergy drug license deal** Brokerage H.C. Wainwright upgrades drug developer Rapt Therapeutics RAPT.O to 'buy' from 'neutral'** Co entered into a license agreement with China-based Shanghai Jemincare Pharmaceutical Co for an experimental allergy treatment called RPT904** RAPT plans to develop RPT904 initially for food allergy** Brokerage says \"investors should note that the food allergy market represents a large and lucrative niche,\" estimates that about 33 mln people suffer from at least one food allergy in the US ** Brokerage projects peak annual sales of $5.4 bln by 2037 for RPT904, assuming U.S. launch in 2031** Says RPT904 could achieve peak sales approaching $500M for chronic spontaneous urticaria (CSU) — a skin condition** Brokerage estimates a 40% probability of approval of RPT904 for food allergy and a 30% probability of approval for CSU** Up to last close, stock down 93% YTD  (Reporting by Sneha S K) ((Sneha.SK@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}